×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
LLY – eli lilly and company (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
LLY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/20
08:30 pm
lly
US Approves First Drug Treatment For Sleep Apnea [Barron's]
Neutral
Report
US Approves First Drug Treatment For Sleep Apnea [Barron's]
12/20
06:33 pm
lly
FDA approves weight-loss drug Zepbound for obstructive sleep apnea [CNN]
Neutral
Report
FDA approves weight-loss drug Zepbound for obstructive sleep apnea [CNN]
12/20
06:01 pm
lly
Novo Nordisk stock plunges 20% after a trial of its latest weight loss drug disappoints [Yahoo! Finance]
Neutral
Report
Novo Nordisk stock plunges 20% after a trial of its latest weight loss drug disappoints [Yahoo! Finance]
12/20
05:58 pm
lly
FDA approves weight loss drug Zepbound for sleep apnea [MSNBC.com]
Low
Report
FDA approves weight loss drug Zepbound for sleep apnea [MSNBC.com]
12/20
05:41 pm
lly
FDA Approves First Medication for Obstructive Sleep Apnea [Yahoo! Finance]
Neutral
Report
FDA Approves First Medication for Obstructive Sleep Apnea [Yahoo! Finance]
12/20
05:30 pm
lly
Zepbound Approved For Sleep Apnea [Forbes]
Neutral
Report
Zepbound Approved For Sleep Apnea [Forbes]
12/20
05:05 pm
lly
FDA approves weight-loss drug Zepbound for obstructive sleep apnea [CNN]
Low
Report
FDA approves weight-loss drug Zepbound for obstructive sleep apnea [CNN]
12/20
05:03 pm
lly
Eli Lilly's Zepbound gains sleep apnea indication [Seeking Alpha]
Low
Report
Eli Lilly's Zepbound gains sleep apnea indication [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/17
04:23 pm
lly
Form 4 ELI LILLY & Co For: Dec 16 Filed by: Sulzberger Gabrielle
Low
Report
Form 4 ELI LILLY & Co For: Dec 16 Filed by: Sulzberger Gabrielle
12/17
04:22 pm
lly
Form 4 ELI LILLY & Co For: Dec 16 Filed by: LUCIANO JUAN R
Low
Report
Form 4 ELI LILLY & Co For: Dec 16 Filed by: LUCIANO JUAN R
12/17
04:20 pm
lly
Form 4 ELI LILLY & Co For: Dec 16 Filed by: JOHNSON KIMBERLY H
Low
Report
Form 4 ELI LILLY & Co For: Dec 16 Filed by: JOHNSON KIMBERLY H
12/17
04:18 pm
lly
Form 4 ELI LILLY & Co For: Dec 16 Filed by: Hedley Mary Lynne
Low
Report
Form 4 ELI LILLY & Co For: Dec 16 Filed by: Hedley Mary Lynne
12/17
04:17 pm
lly
Form 4 ELI LILLY & Co For: Dec 16 Filed by: Alvarez Ralph
Low
Report
Form 4 ELI LILLY & Co For: Dec 16 Filed by: Alvarez Ralph
12/4
04:20 pm
lly
Form 3 ELI LILLY & Co For: Dec 01 Filed by: Moeller Jon R
Low
Report
Form 3 ELI LILLY & Co For: Dec 01 Filed by: Moeller Jon R
11/20
04:30 pm
lly
Form 4 ELI LILLY & Co For: Nov 18 Filed by: Walker Karen
Low
Report
Form 4 ELI LILLY & Co For: Nov 18 Filed by: Walker Karen
11/20
04:29 pm
lly
Form 4 ELI LILLY & Co For: Nov 18 Filed by: Sulzberger Gabrielle
Low
Report
Form 4 ELI LILLY & Co For: Nov 18 Filed by: Sulzberger Gabrielle
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/12
Eli Lilly, AbCellera Biologics to co-develop coronavirus therapies [Reuters]
14.2%
3/2 U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis 5.8%
4/13 Despite Qualms, Arthritis Drug to Be Tested in Coronavirus Study [The New York Times] 4.6%
4/2 Eli Lilly And Co (NYSE: LLY) had its price target lowered by analysts at Morgan Stanley from $150.00 to $148.00. They now have an "overweight" rating on the stock. 4.2%
3/23 FDA enacts abbreviated approval pathway for insulin biosimilars [Seeking Alpha] 3.2%
4/16 Lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® now available 3.2%
10/28 Insider Buying: The Eli Lilly and Company (NYSE:LLY) Chairman Just Bought US$500k Worth Of Shares [Yahoo! Finance News] 2.7%
2/4 Form 4 ELI LILLY & Co For: Feb 01 Filed by: Zulueta Alfonso G 2.7%
12/18 Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm) 2.7%
3/23 Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic 2.6%
3/2 U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis 5.8%
4/13 Despite Qualms, Arthritis Drug to Be Tested in Coronavirus Study [The New York Times] 4.6%
4/2 Eli Lilly And Co (NYSE: LLY) had its price target lowered by analysts at Morgan Stanley from $150.00 to $148.00. They now have an "overweight" rating on the stock. 4.2%
3/23 FDA enacts abbreviated approval pathway for insulin biosimilars [Seeking Alpha] 3.2%
4/16 Lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® now available 3.2%
10/28 Insider Buying: The Eli Lilly and Company (NYSE:LLY) Chairman Just Bought US$500k Worth Of Shares [Yahoo! Finance News] 2.7%
2/4 Form 4 ELI LILLY & Co For: Feb 01 Filed by: Zulueta Alfonso G 2.7%
12/18 Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm) 2.7%
3/23 Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic 2.6%
TOP News Decliners
3/11
Eli Lilly to Participate in Program to Make Insulin Cheaper for Seniors [The Motley Fool]
-10.0%
3/18 Hap Sneddon's Top Picks: March 18, 2020 [Business News Network (BNN) Energy & Resources (Canada)] -7.6%
3/20 Form DEFA14A ELI LILLY & Co -5.8%
7/11 New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache -5.3%
6/9 Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions -4.0%
8/14 Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health -4.0%
4/28 Form 8-K ELI LILLY & Co For: Apr 24 -3.5%
2/27 Local Organization NOVA ScriptsCentral Benefits BIG with Eli Lilly release of Bulk Donation Insulin Pens -3.4%
2/21 Trulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease -3.4%
8/5 Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments -3.4%
3/18 Hap Sneddon's Top Picks: March 18, 2020 [Business News Network (BNN) Energy & Resources (Canada)] -7.6%
3/20 Form DEFA14A ELI LILLY & Co -5.8%
7/11 New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache -5.3%
6/9 Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions -4.0%
8/14 Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health -4.0%
4/28 Form 8-K ELI LILLY & Co For: Apr 24 -3.5%
2/27 Local Organization NOVA ScriptsCentral Benefits BIG with Eli Lilly release of Bulk Donation Insulin Pens -3.4%
2/21 Trulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease -3.4%
8/5 Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments -3.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: